NEW YORK (TheStreet) -- Shares of OraSure Technologies (OSUR) were jumping 8.41% to $8.51 on heavy trading volume early Monday afternoon as Stephens raised its rating on the stock to "overweight" from "equal weight," the Fly reports.
The firm also upped its price target to $11 from $7.50 on shares of the Bethlehem, PA-based medical device company.
Stephens cited a possible acceleration in the company's product revenue growth, the Fly noted.
OraSure develops and manufactures diagnostic products, oral fluid specimen collection devices, laboratory diagnostic products and other medical devices.
About 2.04 million of the company's shares changed hands so far today vs. its average 30-day volume of 715,126 shares per day.
(OraSure is held in David Peltier's Stocks Under $10 portfolio. See all of his holdings with a free trial.)
Separately, TheStreet Ratings Team has a "Hold" rating with a score of C+ on the stock.
The primary factors that have impacted the rating are mixed. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance.
But the team also finds that the company's return on equity has been disappointing.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: OSUR